Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
Last trade$8.32
Day change-$0.18 (-2.12%)
Day range$8.11 – $8.69
Volume1,602,825
Market cap$551M
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$551.01M
Price / earnings
—
Price / book
1.4×
Price / sales
5.47×
EV / sales
4.63×
EV / EBITDA
-2.33×
Profitability
Earnings per share
-$3.87
Return on assets
-26.58%
Return on equity
-63.93%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.72×
Quick ratio
4.72×
Cash ratio
1.28×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$173.54M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for DNA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$27.71M
$20.16M
$19.47M
$33.4M
$29.38M
$39.13M
$38.23M
$43.85M
Cost of revenue
$1.81M
$1.72M
$3.1M
$7.3M
$4.63M
$5.38M
$4.09M
$9.62M
Gross profit
$25.91M
$18.44M
$16.38M
$26.1M
$24.76M
$33.75M
$34.14M
$34.23M
Selling, general and administrative
$28.59M
$30.78M
$37.83M
$46.01M
$36.99M
$34.98M
$39.72M
$57.3M
Research and development
$40.95M
$46.21M
$49.92M
$50.13M
$69.35M
$53.37M
$70.92M
$76.38M
Total operating expenses
$69.54M
$76.99M
$94.9M
$96.85M
$107.06M
$91.92M
$119.75M
$137.83M
Operating income
-$43.63M
-$58.55M
-$78.52M
-$70.75M
-$82.31M
-$58.16M
-$85.61M
-$103.61M
Interest expense
$0
$0
$0
-$17.91M
$0
$0
$0
-$31.37M
Income before taxes
-$41.26M
-$57.19M
-$76.14M
-$81.39M
-$73.35M
-$53.48M
-$83.22M
-$107.86M
Income taxes
-$271K
$128K
-$80K
-$643K
$1K
-$283K
$88K
-$325K
Net income
-$40.98M
-$46.71M
-$82.59M
-$80.75M
-$80.76M
-$60.3M
-$90.96M
-$107.53M
Net income attributable to common shareholders
-$40.98M
-$46.71M
-$82.59M
-$80.75M
-$80.76M
-$60.3M
-$90.96M
-$107.53M
EBITDA
-$31.6M
-$46.23M
-$65.72M
-$56.38M
-$67.96M
-$39.35M
-$66.32M
-$83.8M
Basic earnings per share
-$0.64
-$0.75
-$1.39
-$1.41
-$1.45
-$1.10
-$1.68
-$2.00
Diluted earnings per share
-$0.64
-$0.75
-$1.39
-$1.41
-$1.45
-$1.10
-$1.68
-$2.00
Recent news
Company coverage with links to the original publishers.
Ginkgo Bioworks announced a strategic shift toward commercializing autonomous laboratory hardware and cloud data services. The company secured its first major pharma partnership with Novo Nordisk to build an autonomous lab, improved liquidity with $285 million in cash and no debt, and reduced R&D expenses by 48% year-over-year. The company is positioning itself to capitalize on AI developers' demand for physical laboratory data generation.
Ginkgo Bioworks (DNA) closed at $12.74, down 4.35%, significantly underperforming the S&P 500's 0.31% decline. While the stock gained 3.82% over the past month, upcoming earnings are expected to show an EPS of -$0.58 and revenue of $20.5 million, down 47.22% year-over-year. The company holds a Zacks Rank of #3 (Hold) with stagnant consensus estimates.
Cathie Wood's Ark Invest has been buying Archer Aviation stock during its 62% decline, but the article examines Ark's track record of buying beaten-down stocks. Ark Innovation ETF has underperformed the S&P 500 by 110% over five years, with notable losses in past holdings like Teladoc (down 95%), Zoom (down 65%), and Ginkgo Bioworks (down 98%). The article cautions that investors should evaluate Archer based on its own business fundamentals and catalysts rather than Ark's historical performance.
Ginkgo Bioworks (DNA) declined 2.09% to $9.86 while the broader market gained, underperforming despite a 26.19% monthly gain. The company faces headwinds with expected quarterly losses of $0.58 per share and a 47.22% revenue decline year-over-year. Analysts maintain a Hold rating (Zacks Rank #3) with full-year revenue projected at $82.2 million, down 51.69% from the prior year.
Ginkgo Bioworks Holdings (DNA) declined 1.96% to $11.53, underperforming the S&P 500's 1.11% loss on October 14, 2026. Despite a strong 68.24% monthly gain, the company faces headwinds with expected EPS of -$0.58 and revenue projected to decline 47.22% quarter-over-quarter. Full-year estimates show -$3.2 EPS and 51.69% revenue decline. The stock holds a Zacks Rank #3 (Hold) rating with unchanged consensus estimates over the past 30 days.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.